Obesity: Post-Pandemic Weight Management

Area of Science:

• Pediatric Endocrinology
• Public Health
• Medical Ethics

Background:

• The coronavirus disease 2019 (COVID-19) pandemic exacerbated societal issues, contributing to a rise in adolescent obesity.
• Increased awareness of weight stigma and size bias emerged alongside the pandemic.
• The American Academy of Pediatrics released new clinical guidelines for adolescent obesity during this period.

Purpose of the Study:

• To examine the intersection of societal changes, clinical guidelines, and pharmaceutical advancements in adolescent obesity care.
• To assess the availability of insurance coverage for newly approved weight loss medications for adolescents.

Main Methods:

• Review of societal trends and their impact on adolescent weight.
• Analysis of American Academy of Pediatrics guidelines.
• Examination of Food and Drug Administration approvals for adolescent weight loss drugs.
• Investigation of insurance coverage policies for these treatments.

Main Results:

• The COVID-19 pandemic correlated with increased adolescent obesity prevalence.
• New clinical practice guidelines and weight loss medications for adolescents were approved.
• Significant gaps exist in insurance coverage for these new adolescent obesity treatments.

Conclusions:

• Societal shifts during the pandemic intensified the adolescent obesity crisis.
• While medical advancements offer new hope, lack of insurance coverage presents a major barrier to treatment access.
• Urgent attention is needed to address insurance disparities for effective adolescent obesity management.